Wenyi Wang
Affiliations: | Georgia State University, Atlanta, GA, United States |
Google:
"Wenyi Wang"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lu B, Hu E, Ding W, et al. (2023) Bioinspired Hemostatic Strategy via Pulse Ejections for Severe Bleeding Wounds. Research (Washington, D.C.). 6: 0150 |
| Yang X, Pan Z, Choudhury MR, et al. (2020) Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery. Medicinal Research Reviews |
| Chatterjee S, Hui PC, Kan CW, et al. (2019) Dual-responsive (pH/temperature) Pluronic F-127 hydrogel drug delivery system for textile-based transdermal therapy. Scientific Reports. 9: 11658 |
| Wang W, Wang B. (2018) SO Donors and Prodrugs, and Their Possible Applications: A Review. Frontiers in Chemistry. 6: 559 |
| Wang W, Wang B. (2017) Esterase-sensitive sulfur dioxide prodrugs inspired by modified Julia olefination. Chemical Communications (Cambridge, England) |
| Wang W, Ji X, Du Z, et al. (2017) Sulfur dioxide prodrugs: triggered release of SO2via a click reaction. Chemical Communications (Cambridge, England) |
| Wang WY, Hui PCL, Wat E, et al. (2016) Enhanced Transdermal Permeability via Constructing the Porous Structure of Poloxamer-Based Hydrogel. Polymers. 8 |
| Wang W, Hui PC, Wat E, et al. (2016) In vitro drug release and percutaneous behavior of poloxamer-based hydrogel formulation containing traditional Chinese medicine. Colloids and Surfaces. B, Biointerfaces. 148: 526-532 |
| Wang W, Wat E, Hui PC, et al. (2016) Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment. Scientific Reports. 6: 24112 |
| Bowlin SJ, Xia F, Wang W, et al. (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clinic Proceedings. 88: 139-48 |